Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 5/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ATP4A | P20648 | 1/20 | 0.31 |
| ▸ | ATP4B | P51164 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020719 | 0.84 | ALDH1A1 (0.47) | MAPTDAOALDH1A1CSNK2A1TYMS | |
| SCHEMBL3711999 | 0.84 | DAO (0.37) | MAPTDAOALDH1A1TYMS | |
| Benzimidazole SCHEMBL7413340 | 0.81 | ALDH1A1 (0.35) | MAPTALDH1A1PARP1ATP4AATP4B | |
| SCHEMBL1625968 | 0.79 | HCAR1 (0.33) | CSNK2A2CSNK2BCSNK2A1HCAR1 | |
| SCHEMBL13542739 | 0.78 | KDM4E (0.40) | MAPTDAOALDH1A1TYMSLMNA | |
| SCHEMBL7345392 | 0.78 | PDE3B (0.42) | MAPTALDH1A1 | |
| SCHEMBL31569587 | 0.75 | PIN1 (0.50) | MAPTDAOCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL6139156 | 0.72 | PARP1 (0.41) | DAOALDH1A1PARP1 | |
| SCHEMBL66296 | 0.71 | NOS1 (0.44) | MAPTDAOALDH1A1TYMSPARP1 | |
| SCHEMBL1192890 | 0.69 | GRIN2D (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2012-02-23 | — | — | US | disclosed |
| EP-2349999-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | Universität des Saarlandes (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010043711-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | UNIVERSITAET DES SAARLANDES (DE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046307-A1 | ALLOSTERIC PROTEIN KINASE MODULATORS | AURKC, AURKA, AURKB | MAPT 964/4885DAO 4399/4885ALDH1A1 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.